skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
MAGE-A1/MAGE-A3/NY-ESO-1 Peptides Vaccine (Code C84854)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: MAGE-A1/MAGE-A3/NY-ESO-1 Peptides Vaccine

Definition: A cancer vaccine comprised of synthetic peptides derived from human melanoma antigen A1 (MAGE-A1), human melanoma antigen A3 (MAGE-A3) and cancer-testis antigen NY-ESO-1 with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A1/MAGE-A3/NY-ESO-1 peptides vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A1, MAGE-A3 and NY-ESO-1, resulting in tumor cell lysis. The MAGE-A1, MAGE-A3, and NY-ESO-1 tumor-associated antigens (TAAS) are overexpressed by a variety of cancer cell types.

Label: MAGE-A1/MAGE-A3/NY-ESO-1 Peptides Vaccine

NCI Thesaurus Code: C84854 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL412412  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
MAGE-A1/MAGE-A3/NY-ESO-1 Peptides Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 651378
PDQ Open Trial Search ID 651378 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C84854
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom